D
Dae Joon Kim
Researcher at University of Texas at Austin
Publications - 50
Citations - 1781
Dae Joon Kim is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Cell growth & Carcinogenesis. The author has an hindex of 20, co-authored 46 publications receiving 1492 citations. Previous affiliations of Dae Joon Kim include University of Cincinnati Academic Health Center & Pennsylvania State University.
Papers
More filters
Journal ArticleDOI
The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiation
TL;DR: Recent studies revealed that ligand activation of PPARβ can induce fatty acid catabolism in skeletal muscle and is associated with improved insulin sensitivity, attenuated weight gain and elevated HDL levels thus demonstrating promising potential for targeting PPAR β for treating obesity, dyslipidemias and type 2 diabetes.
Journal ArticleDOI
PPARβ/δ selectively induces differentiation and inhibits cell proliferation
Dae Joon Kim,Moses T. Bility,Andrew N. Billin,Timothy M. Willson,Frank J. Gonzalez,Jeffrey M. Peters +5 more
TL;DR: Ligand activation of PPARβ could be a novel approach to selectively induce differentiation and inhibit cell proliferation, thus representing a new molecular target for the treatment of skin disorders resulting from altered cell proliferation such as psoriasis and cancer.
Journal ArticleDOI
GFRA1 promotes cisplatin-induced chemoresistance in osteosarcoma by inducing autophagy
Mihwa Kim,Ji Yeon Jung,Seung-Ho Choi,Hyunseung Lee,Liza D. Morales,Jeong Tae Koh,Sun Hun Kim,Yoo Duk Choi,Chan Choi,Thomas J. Slaga,Won Jae Kim,Dae Joon Kim +11 more
TL;DR: It is demonstrated that GFRA1/GFRα1 (GDNF family receptor α 1), contributes to cisplatin-induced chemoresistance by regulating autophagy in osteosarcoma, and it is suggested thatGFRA1-mediated autophileagy is a promising novel target for overcoming cisPlatin resistance in ostea.
Journal ArticleDOI
Protein Tyrosine Phosphatases as Potential Regulators of STAT3 Signaling.
TL;DR: There are seven PTPs that have been shown to dephosphorylate STAT3 and, thereby, regulate STAT3 signaling and have great potential as targets for the development of more effective therapies against human disease, including cancer.
Journal ArticleDOI
Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis
TL;DR: Signal transducer and activator of transcription 3 (Stat3) is one of a family of cytoplasmic proteins that participate in normal cellular responses to cytokines and growth factors as transcription factors, and its constitutive activation is associated with a number of human epithelial cancers.